LEXINGTON, Mass. / Jul 07, 2025 / Business Wire / Agenus Inc. (Nasdaq: AGEN) a leader in immuno-oncology innovation, today announced that its botensilimab and balstilimab (BOT/BAL) combination achieved a two-year survival rate of 42% along with a now more mature 21-month median overall survival (OS) in an expanded cohort of 123 patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver... Read More

Partnership aims to accelerate precision immunotherapy by leveraging AI-powered virtual cell models to identify which patients are most likely to benefit from BOT/BAL treatment Collaboration builds on landmark 2024 Cancer Discovery study elucidating botensilimab’s unique FcγR-mediated immune activation underlying activity in refractory tumors. Supports AI-enabled biomarker discovery, aligning with the national priorities and... Read More

LEXINGTON, Mass. / Jun 10, 2025 / Business Wire / Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit... Read More

$75M upfront payment to Agenus for the transfer of manufacturing assets $50M of contingent payments to Agenus Exclusive license for BOT/BAL in India and Sri Lanka $16M equity investment at $7.50 per share LEXINGTON, Mass. / Jun 03, 2025 / Business Wire / Agenus Inc . ( Nasdaq: AGEN ), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE:... Read More

Study shows botensilimab “switches on” the body’s own T-cells to attack a common, treatment-resistant form of colorectal cancer LEXINGTON, Mass. / May 30, 2025 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented new translational data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study demonstrates that botensilimab-based therapy induces a robust and... Read More

Presenting new data in the most mature readout to date, with 60% more patients and reported median and 2-year overall survival. LEXINGTON, Mass. / May 15, 2025 / Business Wire / Agenus Inc . (“Agenus” or the Company”) (NASDAQ: AGEN) , a leader in immuno-oncology, today announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab (BOT/BAL) in patients with microsatellite stable (MSS) metastatic... Read More

BOT/BAL Achieves Breakthrough Response Rates in MSS Cancers — Oral AACR Data Spotlight Pan-Tumor Neoadjuvant Success Seasoned Leader Onboard to Accelerate BOT/BAL Toward Registration Milestones Near-Term Capital Transaction Poised to Bolster Liquidity LEXINGTON, Mass. / May 12, 2025 / Business Wire / Agenus Inc . (“Agenus” or the “Company”) (NASDAQ: AGEN) , a leader in immuno-oncology, today reported financial and... Read More

LEXINGTON, Mass. / May 12, 2025 / Business Wire / Agenus Inc. (Nasdaq: AGEN) , a leader in immuno-oncology innovation today announced that Dr. Richard M. Goldberg, an internationally recognized expert in gastrointestinal (GI) cancer treatment and research, has joined the company as Chief Development Officer. In this role, Dr. Goldberg will lead efforts to advance the botensilimab/balstilimab (BOT/BAL) program for patients... Read More

LEXINGTON, Mass. / Apr 29, 2025 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before the market opens on Monday, May 12 th . Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate... Read More

Initial results from NEOASIS demonstrate BOT/BAL efficacy in the neoadjuvant setting across multiple MSS and MSI-H solid tumors LEXINGTON, Mass. / Apr 28, 2025 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that data from the investigator sponsored NEOASIS study were presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting in Chicago,... Read More

Durable responses observed in heavily pretreated HCC patients who progressed on approved immunotherapies LEXINGTON, Mass. / Apr 25, 2025 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (HCC) cohort of its ongoing Phase 1 study evaluating botensilimab (BOT) in combination with balstilimab (BAL). These findings are being... Read More

LEXINGTON, Mass. / Apr 23, 2025 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced three upcoming presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3 in Chicago, Illinois. A poster presentation will highlight new translational data monitoring induced T-cell dynamics from the botensilimab and balstilimab (BOT/BAL) program... Read More

First oral presentation of BOT/BAL neoadjuvant results from the NEOASIS trial in MSI-H and MSS solid tumors New data from the treatment-refractory hepatocellular carcinoma (HCC) cohort of the BOT/BAL Phase 1 trial to be presented LEXINGTON, Mass. / Mar 25, 2025 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research... Read More

Patients and Healthcare Providers Alike Call for More Innovative, Less Toxic Treatment Options CRC Diagnoses Rise While Current Standards Fall Short LEXINGTON, Mass. / Mar 19, 2025 / Business Wire / Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today announced the results of its national Colorectal Cancer in Focus survey, highlighting critical unmet needs and... Read More

LEXINGTON, Mass. / Mar 11, 2025 / Business Wire / Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational results for Q4 and full-year 2024, highlighting strategic measures to substantially reduce operational costs while preserving and enhancing the potential of its leading BOT/BAL program. "In line with our strategic... Read More

LEXINGTON, Mass. / Feb 26, 2025 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer immunotherapy. Agenus is advancing a robust clinical pipeline targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, tumor microenvironment conditioning agents and... Read More

LEXINGTON, Mass. / Feb 25, 2025 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced participation in a panel discussion at the B. Riley Securities Precision Oncology & Radiopharma Investor Conference that will take place on Friday, February 28th in New York. Panel Discussion Details: Speaker: Robin Taylor, Ph.D., Chief Commercial Officer Topic : “What It Takes to Move the Needle in... Read More

LEXINGTON, Mass. / Feb 25, 2025 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 11 th . Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and... Read More

Combination of Botensilimab/Balstilimab with MiNK Therapeutics’ AgenT-797 Shows Strong Immune Activation and Potential to Enhance Outcomes in Refractory Gastric Cancer LEXINGTON, Mass. / Feb 24, 2025 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting in Los Angeles, California. The oral presentation... Read More

LEXINGTON, Mass. / Feb 23, 2025 / Business Wire / Proffered Papers, Session 2, Session Date and Time of release dated February 12, 2025, should read: Monday, February 24 th , 1:39-1:45 p.m. PST (instead of Tuesday, February 25 th , 1:00-1:45 p.m. PST). The updated release reads: AGENUS’ BOT/BAL SELECTED FOR TWO PRESENTATIONS AT UPCOMING AACR IO ANNUAL MEETING Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today... Read More

LEXINGTON, Mass. / Feb 12, 2025 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. An oral presentation will highlight interim data from the ongoing Phase 2 study of botensilimab and... Read More

LEXINGTON, Mass. / Jan 29, 2025 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab (BOT) in combination with balstilimab (BAL) in patients with relapsed/refractory (R/R) metastatic sarcomas. These findings further reinforce the consistency of the BOT/BAL combination, which has already shown... Read More

Results from two independent neoadjuvant studies in the U.S. and Europe, enrolling more than 80 patients, underscore BOT/BAL’s potential to enable chemo-free and non-operative approaches in colorectal cancer (CRC). New randomized Phase 2 results in over 230 patients with refractory MSS mCRC, consistent with Phase 1 data, demonstrate durable responses and a favorable safety profile. Strong activity demonstrated with BOT/BAL... Read More

Presentations will showcase new data reinforcing BOT/BAL’s potential across different lines of treatment in colorectal cancer, including the neoadjuvant setting LEXINGTON, Mass. / Dec 18, 2024 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (BAL, an anti-PD-1 antibody) at the... Read More

LEXINGTON, Mass. / Dec 05, 2024 / Business Wire / Agenus Inc. , a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial position, and prioritizing the advancement of its most impactful programs as it prepares for 2025. Reductions are designed to reduce cash burn to $100 million in FY 2025. This initiative follows the successful... Read More

LEXINGTON, Mass. / Nov 27, 2024 / Business Wire / Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation has successfully secured a $22 million non-amortizing mortgage backed by its Berkeley-based Biologics CMC facility ("901 Heinz") and its 66-acre biomanufacturing-zoned property in Vacaville, California. Facilitated by L&L Capital, the transaction yields $20 million in net... Read More

Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations LEXINGTON, Mass. / Nov 12, 2024 / Business Wire / Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024. “BOT/BAL represents one of the most significant advancements in cancer immunotherapy,... Read More

Novel Candidates Show Promise in Turning Cold and Refractory Tumors into Responsive Targets LEXINGTON, Mass. / Nov 07, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational immunotherapy candidates, botensilimab and AGEN1721, at the Society for Immunotherapy... Read More

LEXINGTON, Mass. / Nov 05, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2024 financial results before the market opens on Tuesday, November 12 th , 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide... Read More

BOT/BAL Demonstrates Broad and Durable Activity in Advanced Sarcoma Population LEXINGTON, Mass. / Sep 13, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, presented data today at the European Society for Medical Oncology (ESMO) Congress held in Barcelona, Spain. The data from a Phase 1 study of botensilimab (BOT), an investigational... Read More

LEXINGTON, Mass. / Sep 09, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be featured in a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress, taking place September 13-17, 2024, in... Read More

LEXINGTON, Mass. / Sep 03, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Agenus executives, Dr. Garo Armen, Chief Executive Officer, Robin Taylor, Chief Commercial Officer, and Zack Armen, Head of Investor Relations, will participate in the following upcoming investor conferences: Wells Fargo... Read More

Robust Phase 2 Data Validate Consistent Clinical Activity of BOT/BAL in Metastatic MSS CRC Maturing Data Across BOT/BAL Program Demonstrate Broad Solid Tumor Activity in the Late Stage, First-Line with Chemo Combinations, and Neoadjuvant disease Commenced Interactions with Global Regulatory Authorities for BOT/BAL Approval Pathways Data from ESMO GI Demonstrate Pathologic Complete Responses with BOT/BAL Therapy in... Read More

Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline LEXINGTON, Mass. / Aug 08, 2024 / Business Wire / Agenus Inc. (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising,... Read More

LEXINGTON, Mass. / Aug 07, 2024 / Business Wire / Agenus Inc. (NASDAQ: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the publication of a seminal study in the prestigious Cancer Discovery , a journal of the American Association for Cancer Research, detailing the novel mechanism of action and effectiveness of botensilimab, an investigational, novel multifunctional... Read More

LEXINGTON, Mass. / Jul 26, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a... Read More

Agreement reached with the FDA on Phase 3 dose for the BOT/BAL combination Accelerated approval pathway discouraged by FDA Preliminary Phase 2 data tracks with Phase 1 BOT/BAL clinical activity in MSS mCRC (ORR ~19.4% and 90% alive at 6 months) Strategic meeting with the European agency scheduled for Q3 2024 to explore additional regulatory opportunities LEXINGTON, Mass. / Jul 18, 2024 / Business Wire / Agenus Inc. (NASDAQ:... Read More

Extended BOT/BAL Therapy Yields Pronounced Improvements in Tumor Reductions LEXINGTON, Mass. / Jun 28, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colon cancer. Data were presented at the 2024... Read More

LEXINGTON, Mass. / Jun 27, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using botensilimab (BOT), a human Fc enhanced next-generation anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody,... Read More

Strategic leadership to drive next phase of growth for the company LEXINGTON, Mass. / Jun 17, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the... Read More

BOT/BAL Combination Shows Promising Results in the Most Prevalent Form of Colorectal Cancer, Affecting 95% of Diagnosed Patients LEXINGTON, Mass. / Jun 13, 2024 / Business Wire / Agenus has published results from a groundbreaking clinical trial in Nature Medicine , revealing the potential of a novel immunotherapy combination for treating microsatellite stable metastatic colorectal cancer (MSS mCRC), a cancer type... Read More

LEXINGTON, Mass. / Jun 04, 2024 / Business Wire / Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 11, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders... Read More

LEXINGTON, Mass. / May 24, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted inducement awards to Eric Olson, in connection with his appointment as Head of Regulatory. The Compensation Committee approved the awards pursuant to Agenus'... Read More

New analysis highlights BOT/BAL activity across challenging metastatic disease sites LEXINGTON, Mass. / May 23, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced a novel analysis from the Phase 1b trial of botensilimab in combination with balstilimab (BOT/BAL) in relapsed/refractory microsatellite stable colorectal cancer... Read More

LEXINGTON, Mass. / May 23, 2024 / Business Wire / Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, and Robin Taylor, Chief Commercial Officer, will participate in a fireside chat and investor one-on-ones at the upcoming Goldman Sachs Global Healthcare Conference on June 10 th – 13 th in... Read More

LEXINGTON, Mass. / May 16, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the U.S. Food and Drug Administration (FDA) to discuss the botensilimab plus balstilimab (BOT/BAL) combination therapy studies in patients with relapsed/refractory... Read More

$100M royalty financing agreement with Ligand announced, bringing in capital via non-equity means to support critical botensilimab/balstilimab (BOT/BAL) development and launch readiness activities Company has reestablished its market compliance with Nasdaq Listing Notable clinical results observed in Phase 1 and Phase 2 studies of BOT/BAL in metastatic relapsed/refractory colorectal cancer setting (r/r MSS CRC NLM)... Read More

LEXINGTON, Mass. / May 01, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immunology-based therapies for cancer, received notice from NASDAQ on April 30, 2024, that the Company has regained compliance with the $1.00 minimum bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2). Accordingly, the Company now satisfies all requirements for continued listing on the NASDAQ Capital Market and... Read More

LEXINGTON, Mass. / Apr 24, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced an upcoming presentation from the Phase 1b trial of botensilimab in combination with balstilimab (“BOT/BAL”) in patients with relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases (r/r MSS CRC NLM) will be... Read More

LEXINGTON, Mass. / Apr 23, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a... Read More

Updated Phase 1 data demonstrate a 12-month overall survival (OS) of 71% and 18-month OS of 62% Company plans to discuss encouraging Phase 2 interim results with the FDA Company plans to submit Phase 2 data to a major medical conference in the second half of 2024 LEXINGTON, Mass. / Apr 12, 2024 / Business Wire / Agenus Inc. (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various... Read More

LEXINGTON, Mass. / Apr 05, 2024 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced its stockholders have approved a one-for-twenty reverse stock split of its issued and outstanding common stock, which will go into effect at 12:01 a.m., Eastern Time on April 12, 2024. The reverse stock split is intended to give Agenus... Read More

FDA Grants Fast Track designation for BOT/BAL in metastatic, refractory colorectal cancer (CRC) patients who have failed 1 st and 2 nd line standard of care treatments Data from Phase 1 of BOT/BAL in refractory CRC showed durable ORR of 24% in patients with non-active liver metastases (NLM); Completed enrollment of randomized Phase 2 trial (n=230) Clinical data sets path for expansion opportunities in pancreas, lung,... Read More

Preclinical findings demonstrate superior pharmacological activity, offering a differentiated mechanism-of-action to enhance anti-tumor immunity in advanced solid cancers LEXINGTON, Mass. / Mar 06, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777)... Read More

LEXINGTON, Mass. / Mar 05, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted inducement awards to Nils Eckardt, Kent Barnes, and Brian Greenblatt, in connection with their appointments as Chief Medical Affairs Officer, Head of Marketing... Read More

Conference Call on Thursday, March 14, 2024 at 8:30 a.m. ET LEXINGTON, Mass. / Feb 29, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Company will release its fourth quarter and year end 2023 financial results before the market opens on Thursday, March 14, 2024. Agenus executives will host a... Read More

LEXINGTON, Mass. / Feb 26, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Leerink Global Biopharma Conference on March 11 th - 13 th in Miami Beach, Florida. The fireside chat will take... Read More

LEXINGTON, Mass. / Jan 31, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Oppenheimer Healthcare Conference on February 13 th - 14 th . The fireside chat will take place at 8:00 a.m. ET on... Read More

Botensilimab/Balstilimab (BOT/BAL) shows major tumor regression in 67.5% of Patients with Localized MSS Colorectal Cancer (CRC), a tumor typically unresponsive to IO therapy The study achieved durable elimination of ctDNA, a critical biomarker for cancer clearance and long-term disease-free survival LEXINGTON, Mass. / Jan 22, 2024 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in developing immunological cancer... Read More

LEXINGTON, Mass. / Jan 05, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted, as of January 2, 2024 (“Grant Date”), inducement awards to Manuel Duenas and Benny Johnson in connection with their appointments as Head of Market Access and... Read More

LEXINGTON, Mass. / Jan 04, 2024 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming B. Riley Virtual Healthcare Conference on January 18 th . The fireside chat will take place at 3:00 p.m. ET on... Read More

LEXINGTON, Mass. / Dec 20, 2023 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that data from an investigator sponsored trial (IST) evaluating botensilimab (BOT, multifunctional CTLA-4 immune activator) in combination with balstilimab (BAL, PD-1 antibody) in neoadjuvant colorectal cancer (CRC) will be... Read More

LEXINGTON, Mass. / Dec 11, 2023 / Business Wire / Agenus Inc . (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced it has triggered the second development milestone payment under its global licensing agreement with Bristol Myers Squibb for BMS-986442, an Fc-enhanced bispecific TIGIT antibody. Agenus will receive a $25 million cash payment from Bristol Myers... Read More

Conference Call on Tuesday, November 7, 2023, at 9:00 a.m. ET LEXINGTON, Mass. / Nov 07, 2023 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the third quarter 2023. Agenus executives will host a conference call and webcast at 9:00 a.m. ET to discuss the results and to provide a corporate update.... Read More

LEXINGTON, Mass. / Oct 26, 2023 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2023 financial results via press release before the market opens on Tuesday, November 7, 2023. About Agenus Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a... Read More

U.S. BLA Filing in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (CRC) Planned for Midyear 2024 Potential Accelerated Filings for Advanced Pancreatic Cancer and Melanoma in 2025 Opportunity to Expand into Early-Stage Cancers Supported by Compelling Neoadjuvant CRC Data Live Webcast Today at 1:00 p.m. EDT LEXINGTON, Mass. / Oct 22, 2023 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in developing novel... Read More

LEXINGTON, Mass. / Oct 21, 2023 / Business Wire / Agenus Inc. (Nasdaq:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced expanded data from the company’s phase 1b study of botensilimab (BOT, multifunctional immune activator) in combination with balstilimab (BAL, anti-PD-1) in patients with advanced sarcomas. The results were presented in an oral presentation at the European... Read More

LEXINGTON, Mass. / Oct 10, 2023 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers today announced completion of the planned patient enrollment in ACTIVATE-Colorectal, a randomized Phase 2 trial in advanced colorectal cancer (CRC) evaluating the efficacy and safety of botensilimab (BOT) as monotherapy and in combination with balstilimab (BAL) or standard... Read More

LEXINGTON, Mass. / Oct 05, 2023 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Company will host a corporate event to discuss advancements in its botensilimab/balstilimab (BOT/BAL) program at the upcoming European Society for Medical Oncology (ESMO) Conference on Sunday, October 22, 2023. Agenus will provide updates from the... Read More

LEXINGTON, Mass. / Sep 01, 2023 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted, as of September 1, 2023 (“Grant Date”), inducement awards to Robin Taylor, Ph.D. in connection with his appointment as Chief Commercial Officer. The Compensation Committee... Read More

LEXINGTON, Mass.LEXINGTON, Mass. / Aug 28, 2023 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in the following upcoming investor conferences: 2023 Wells Fargo Healthcare Conference – Fireside chat presentation will be held in-person on Thursday, September 7th, 2023, at... Read More

Strategic Prioritization to Deliver Savings of $40M Through End of 2023 LEXINGTON, Mass. / Aug 23, 2023 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a pioneer in immuno-oncology, today announced a strategic initiative to prioritize and focus resources to accelerate the development, registration, and commercialization of its flagship program botensilimab/balstilimab (BOT/BAL). Under this new plan, Agenus will... Read More

Successful production of STIMULON™ cpcQS-21, a cultured plant cell adjuvant with confirmed biochemical comparability to traditional bark extract-derived adjuvant Submission of Master File (MF) for STIMULON cpcQS-21 to the U.S. FDA for reference by partners as part of regulatory submissions Ongoing collaboration with Ginkgo Bioworks to drive innovation in SaponiQx's adjuvant pipeline through generative molecular design... Read More

LEXINGTON, Mass. / Aug 08, 2023 / Business Wire / Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results for the second quarter 2023. Key accomplishments and highlights include: Botensilimab Update: Botensilimab/balstilimab combination data presented at ESMO-GI demonstrated median overall survival (mOS) of 20.9 months and a 23% overall... Read More

LEXINGTON, Mass. / Jul 28, 2023 / Business Wire / Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN), today announced a data update from the phase 1 expansion cohort of botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) for patients with advanced, refractory sarcomas has been selected for an oral presentation at the upcoming ESMO Congress, to be held October 20 – 24,... Read More

Company Announces Participation in BTIG Virtual Biotechnology Conference LEXINGTON, Mass. / Jul 26, 2023 / Business Wire / Immuno-oncology leader, Agenus (Nasdaq: AGEN), today announced the Company will release its second quarter 2023 financial results via press release before the market opens on Tuesday, August 8, 2023. In addition, Dr. Garo Armen, Chairman and CEO of Agenus, will participate in the following upcoming... Read More

Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer Stephanie Fagan Appointed Chief Communications Officer LEXINGTON, Mass. / Jul 20, 2023 / Business Wire / Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The... Read More

Median Overall Survival of 20.9 Months for Patients Without Active Liver Metastases Surpasses the Recently Reported 12.9-Month Benchmark with Standard of Care in this Population LEXINGTON, Mass. / Jun 30, 2023 / Business Wire / Immuno-oncology leader, Agenus (Nasdaq: AGEN), shared promising data today from its Phase 1b trial on the botensilimab and balstilimab combination at a late-breaking session at the 2023 ESMO World... Read More

AGEN2373 is the first CD137 agonist antibody reporting single agent responses with no major toxicity Responses reported in patients with prostate cancer, ampullary carcinoma and metastatic vulvar squamous cell carcinoma No hepatic toxicities, grade ≥3 treatment-related adverse events, or dose-limiting toxicities were observed at doses up to 10 mg/kg LEXINGTON, Mass. / Jun 05, 2023 / Business Wire / Agenus (Nasdaq: AGEN), a... Read More

LEXINGTON, Mass. / Jun 05, 2023 / Business Wire / Agenus (NASDAQ: AGEN), a leading immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 12, 2023 and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual... Read More

LEXINGTON, Mass. / May 25, 2023 / Business Wire / Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of clinical and preclinical-stage cancer treatments, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Jefferies Healthcare Conference on June 8 th at the Marriot Marquis in New York. The fireside chat will take place... Read More

At a late-breaking presentation at ASCO-GI, botensilimab/balstilimab combination demonstrated a 63% 12-month overall survival rate in metastatic colorectal cancer patients who have failed a median of four prior treatments, more than double the survival rate reported for available treatments Botensilimab/balstilimab combination data update selected for late-breaking oral session at the ESMO-GI conference in June 2023 FDA... Read More

LEXINGTON, Mass. / May 03, 2023 / Business Wire / Agenus (Nasdaq: AGEN), a leading immuno-oncology company dedicated to developing innovative treatments for cancer and infectious diseases, today announced a data update on botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) for patients with non-microsatellite instability-high metastatic colorectal cancer (non-MSI-H mCRC) has been... Read More

Oral presentation on Phase 2 trial evaluating balstilimab/zalifrelimab plus standard of care in advanced sarcoma Poster discussion on Phase 1 trial investigating AGEN2373 monotherapy in advanced solid tumors LEXINGTON, Mass. / Apr 26, 2023 / Business Wire / Agenus (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced plans to present... Read More

Conference Call on Tuesday, May 9, 2023 at 8:30 a.m. ET LEXINGTON, Mass. / Apr 25, 2023 / Business Wire / Agenus (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced the Company will release its first quarter 2023 financial results before the market opens on Tuesday, May 9, 2023. Agenus executives will host a conference call and webcast at... Read More

LEXINGTON, Mass. / Apr 24, 2023 / Business Wire / Agenus (NASDAQ: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced that Dr. Garo Armen, Chairman and CEO, will participate in the following upcoming investor conferences: HC Wainwright BioConnect Investor Conference – Fireside chat presentation will be held in-person at NASDAQ Headquarters in New... Read More

LEXINGTON, Mass. / Apr 17, 2023 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, has been granted Fast Track Designation from the US Food and Drug Administration (FDA) for the investigation of the combination of botensilimab (AGEN1181) and balstilimab (AGEN2034). The designation is for patients with non-microsatellite... Read More

LEXINGTON, Mass. / Mar 30, 2023 / Business Wire / Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that its Board of Directors has declared a dividend of 5 million shares of common stock of its subsidiary, MiNK Therapeutics, Inc. (“MiNK”), to shareholders of Agenus as of April 17, 2023 (the “Record Date”). MiNK is a... Read More

Data presented at plenary session of Society of Gynecologic Oncology Meeting Patients treated suffered from platinum resistant/refractory ovarian cancer Previous PD-(L)1/CTLA-4 combinations have reported only 3-10% responses in comparable patient populations 1,2 Findings consistent with botensilimab/balstilimab benefit in cold and refractory tumors across 9 different solid tumor cancers LEXINGTON, Mass. / Mar 27, 2023 /... Read More

Botensilimab plus balstilimab showed overall response rates of 23% in microsatellite stable colorectal cancer (MSS CRC), 50% in PD-(L)1 refractory non-small cell lung cancer (NSCLC) and in seven additional metastatic, late-line cancers in a total of more than 300 patients Randomized Phase 2 trials in MSS CRC, melanoma, and pancreatic cancers are underway; a confirmatory phase 3 trial in MSS CRC is expected to be launched in... Read More

LEXINGTON, Mass., March 12, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced that it has cancelled its conference call on Monday, March 13 th to discuss its minority cash holdings at Silicon Valley Bank (SVB) in light of the government’s SVB deposit access announcement. About... Read More

LEXINGTON, Mass., March 11, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced that it will hold a conference call to provide detail and to answer any questions regarding its minority cash holdings at Silicon Valley Bank (SVB) at 8:30 a.m. ET on Monday, March 13th. Conference Call... Read More

LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced the Company will release its fourth quarter and full year 2022 financial results before the market opens on Tuesday, March 14, 2023. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to... Read More

LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced plans to present updated data on its lead program botensilimab (Fc-enhanced anti-CTLA-4), at the Society of Gynecologic Oncology (SGO) 37th Annual Meeting on Women’s Cancer, to be held March 25-28 in... Read More

LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO, and Dr. Steven O’Day, Chief Medical Officer, will participate in the following upcoming investor conferences: Guggenheim 5 th Annual Oncology Day – Fireside chat presentation will be held... Read More

Overall response rate (ORR) of 23% and disease control rate (DCR) of 76% in expanded cohort of 70 heavily pre-treated patients; data suggest superior benefit compared to what has been reported for standard of care and other investigational therapies Responses have been durable with 69% ongoing at data cut-off; median overall survival not reached Global, randomized Phase 2 trials of botensilimab/balstilimab in MSS CRC and... Read More

LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven O’Day, Chief Medical Officer, will participate in a virtual fireside chat at the B Riley Securities’ 2023 Virtual Oncology Conference on Wednesday, January 18th at 11:30am ET.... Read More

LEXINGTON, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agenus Inc . (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will present expanded data on botensilimab in combination with balstilimab at the American Society of Clinical Oncology – Gastrointestinal Cancers Symposium (ASCO-GI), to be held... Read More